Millendo announces findings from phase 2b trial of livoletide
JHorsfall • 6 April 2020
Millendo Therapeutics is to discontinue development of livoletide as a potential treatment for Prader-Willi Syndrome.
Biopharmaceutical company Millendo Therapeutics has announced the results of its phase 2b trials of livoletide as a potential treatment for individuals with Prader-Willi Syndrome.
The study found that livoletide did not significantly improve hyperphagia and food-related behaviours. As a result, Millendo has now taken the decision to discontinue the livoletide programme in relation to PWS.
To find out more about the outcome of the study, please visit the Millendo website here.
Changes to our membership offer - and to the way we share our news!
Details of three PWS community days announced in Ayr, Skegness and Dorset!
T ARGET NOW REACHED - THANK YOU! You can still support our work by making a donation here .
Can you help with this important piece of PWS research?
The taster sessions will be FREE and we encourage parents, grandparents and children to join in!
PWSA UK and FPWR UK are kicking off a new collaboration by going orange together!
Our one-day conference for adults with PWS returns for 2023!
Three new videos for Awareness Month from Pilates instructor Joakim Valsinger!
Help us raise funds and awareness of Prader-Willi syndrome
Easter can be a particularly challenging time for families in our PWS community. However, there are ways to celebrate without the need to focus on chocolate.
